Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides

Brian Kavanagh, Andrew Ko, Alan Venook, Kim Margolin, Herbert Zeh, Michael Lotze, Brian Schillinger, Weihong Liu, Ying Lu, Peggie Mitsky, Marta Schilling, Nadege Bercovici, Maureen Loudovaris, Roy Guillermo, Sun Min Lee, James Bender, Bonnie Mills, Lawrence Fong

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Developing a process to generate dendritic cells (DCs) applicable for multicenter trials would facilitate cancer vaccine development. Moreover, targeting multiple antigens with such a vaccine strategy could enhance the efficacy of such a treatment approach. We performed a phase 1/2 clinical trial administering a DC-based vaccine targeting multiple tumor-associated antigens to patients with advanced colorectal cancer (CRC). A qualified manufacturing process was used to generate DC from blood monocytes using granulocyte macrophage colony-stimulating factor and IL-13, and matured for 6 hours with Klebsiella-derived cell wall fraction and interferon-gamma (IFN-γ). DCs were also loaded with 6 HLA-A*0201 binding peptides derived from carcinoembryonic antigen (CEA), MAGE, and HER2/neu, as well as keyhole limpet hemocyanin protein and pan-DR epitope peptide. Four planned doses of 35×10 cells were administered intradermally every 3 weeks. Immune response was assessed by IFN-γ enzyme-linked immunosorbent spot (ELISPOT). Matured DC possessed an activated phenotype and could prime T cells in vitro. In the trial, 21 HLA-A2+ patients were apheresed, 13 were treated with the vaccine, and 11 patients were evaluable. No significant treatment-related toxicity was reported. T-cell responses to a CEA-derived peptide were detected by ELISPOT in 3 patients. T cells induced to CEA possessed high avidity T-cell receptors. ELISPOT after in vitro restimulation detected responses to multiple peptides in 2 patients. All patients showed progressive disease. This pilot study in advanced CRC patients demonstrates DC-generated granulocyte macrophage colony-stimulating factor and IL-13 matured with Klebsiella-derived cell wall fraction and IFN-γ can induce immune responses to multiple tumor-associated antigens in patients with advanced CRC.

Original languageEnglish (US)
Pages (from-to)762-772
Number of pages11
JournalJournal of Immunotherapy
Volume30
Issue number7
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Fingerprint

Major Histocompatibility Complex
Dendritic Cells
Colorectal Neoplasms
Vaccination
Peptides
Immunosorbents
Carcinoembryonic Antigen
Interferon-gamma
Vaccines
Klebsiella
Interleukin-13
Neoplasm Antigens
Granulocyte-Macrophage Colony-Stimulating Factor
T-Lymphocytes
Cell Wall
Enzymes
HLA-A2 Antigen
Clinical Trials, Phase I
Cancer Vaccines
T-Cell Antigen Receptor

Keywords

  • Carcinoembryonic antigen
  • Colorectal cancer
  • Dendritic cell

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. / Kavanagh, Brian; Ko, Andrew; Venook, Alan; Margolin, Kim; Zeh, Herbert; Lotze, Michael; Schillinger, Brian; Liu, Weihong; Lu, Ying; Mitsky, Peggie; Schilling, Marta; Bercovici, Nadege; Loudovaris, Maureen; Guillermo, Roy; Lee, Sun Min; Bender, James; Mills, Bonnie; Fong, Lawrence.

In: Journal of Immunotherapy, Vol. 30, No. 7, 01.10.2007, p. 762-772.

Research output: Contribution to journalArticle

Kavanagh, B, Ko, A, Venook, A, Margolin, K, Zeh, H, Lotze, M, Schillinger, B, Liu, W, Lu, Y, Mitsky, P, Schilling, M, Bercovici, N, Loudovaris, M, Guillermo, R, Lee, SM, Bender, J, Mills, B & Fong, L 2007, 'Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides', Journal of Immunotherapy, vol. 30, no. 7, pp. 762-772. https://doi.org/10.1097/CJI.0b013e318133451c
Kavanagh, Brian ; Ko, Andrew ; Venook, Alan ; Margolin, Kim ; Zeh, Herbert ; Lotze, Michael ; Schillinger, Brian ; Liu, Weihong ; Lu, Ying ; Mitsky, Peggie ; Schilling, Marta ; Bercovici, Nadege ; Loudovaris, Maureen ; Guillermo, Roy ; Lee, Sun Min ; Bender, James ; Mills, Bonnie ; Fong, Lawrence. / Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. In: Journal of Immunotherapy. 2007 ; Vol. 30, No. 7. pp. 762-772.
@article{28503b81da6243fb9d5b7883bf84b62e,
title = "Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides",
abstract = "Developing a process to generate dendritic cells (DCs) applicable for multicenter trials would facilitate cancer vaccine development. Moreover, targeting multiple antigens with such a vaccine strategy could enhance the efficacy of such a treatment approach. We performed a phase 1/2 clinical trial administering a DC-based vaccine targeting multiple tumor-associated antigens to patients with advanced colorectal cancer (CRC). A qualified manufacturing process was used to generate DC from blood monocytes using granulocyte macrophage colony-stimulating factor and IL-13, and matured for 6 hours with Klebsiella-derived cell wall fraction and interferon-gamma (IFN-γ). DCs were also loaded with 6 HLA-A*0201 binding peptides derived from carcinoembryonic antigen (CEA), MAGE, and HER2/neu, as well as keyhole limpet hemocyanin protein and pan-DR epitope peptide. Four planned doses of 35×10 cells were administered intradermally every 3 weeks. Immune response was assessed by IFN-γ enzyme-linked immunosorbent spot (ELISPOT). Matured DC possessed an activated phenotype and could prime T cells in vitro. In the trial, 21 HLA-A2+ patients were apheresed, 13 were treated with the vaccine, and 11 patients were evaluable. No significant treatment-related toxicity was reported. T-cell responses to a CEA-derived peptide were detected by ELISPOT in 3 patients. T cells induced to CEA possessed high avidity T-cell receptors. ELISPOT after in vitro restimulation detected responses to multiple peptides in 2 patients. All patients showed progressive disease. This pilot study in advanced CRC patients demonstrates DC-generated granulocyte macrophage colony-stimulating factor and IL-13 matured with Klebsiella-derived cell wall fraction and IFN-γ can induce immune responses to multiple tumor-associated antigens in patients with advanced CRC.",
keywords = "Carcinoembryonic antigen, Colorectal cancer, Dendritic cell",
author = "Brian Kavanagh and Andrew Ko and Alan Venook and Kim Margolin and Herbert Zeh and Michael Lotze and Brian Schillinger and Weihong Liu and Ying Lu and Peggie Mitsky and Marta Schilling and Nadege Bercovici and Maureen Loudovaris and Roy Guillermo and Lee, {Sun Min} and James Bender and Bonnie Mills and Lawrence Fong",
year = "2007",
month = "10",
day = "1",
doi = "10.1097/CJI.0b013e318133451c",
language = "English (US)",
volume = "30",
pages = "762--772",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides

AU - Kavanagh, Brian

AU - Ko, Andrew

AU - Venook, Alan

AU - Margolin, Kim

AU - Zeh, Herbert

AU - Lotze, Michael

AU - Schillinger, Brian

AU - Liu, Weihong

AU - Lu, Ying

AU - Mitsky, Peggie

AU - Schilling, Marta

AU - Bercovici, Nadege

AU - Loudovaris, Maureen

AU - Guillermo, Roy

AU - Lee, Sun Min

AU - Bender, James

AU - Mills, Bonnie

AU - Fong, Lawrence

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Developing a process to generate dendritic cells (DCs) applicable for multicenter trials would facilitate cancer vaccine development. Moreover, targeting multiple antigens with such a vaccine strategy could enhance the efficacy of such a treatment approach. We performed a phase 1/2 clinical trial administering a DC-based vaccine targeting multiple tumor-associated antigens to patients with advanced colorectal cancer (CRC). A qualified manufacturing process was used to generate DC from blood monocytes using granulocyte macrophage colony-stimulating factor and IL-13, and matured for 6 hours with Klebsiella-derived cell wall fraction and interferon-gamma (IFN-γ). DCs were also loaded with 6 HLA-A*0201 binding peptides derived from carcinoembryonic antigen (CEA), MAGE, and HER2/neu, as well as keyhole limpet hemocyanin protein and pan-DR epitope peptide. Four planned doses of 35×10 cells were administered intradermally every 3 weeks. Immune response was assessed by IFN-γ enzyme-linked immunosorbent spot (ELISPOT). Matured DC possessed an activated phenotype and could prime T cells in vitro. In the trial, 21 HLA-A2+ patients were apheresed, 13 were treated with the vaccine, and 11 patients were evaluable. No significant treatment-related toxicity was reported. T-cell responses to a CEA-derived peptide were detected by ELISPOT in 3 patients. T cells induced to CEA possessed high avidity T-cell receptors. ELISPOT after in vitro restimulation detected responses to multiple peptides in 2 patients. All patients showed progressive disease. This pilot study in advanced CRC patients demonstrates DC-generated granulocyte macrophage colony-stimulating factor and IL-13 matured with Klebsiella-derived cell wall fraction and IFN-γ can induce immune responses to multiple tumor-associated antigens in patients with advanced CRC.

AB - Developing a process to generate dendritic cells (DCs) applicable for multicenter trials would facilitate cancer vaccine development. Moreover, targeting multiple antigens with such a vaccine strategy could enhance the efficacy of such a treatment approach. We performed a phase 1/2 clinical trial administering a DC-based vaccine targeting multiple tumor-associated antigens to patients with advanced colorectal cancer (CRC). A qualified manufacturing process was used to generate DC from blood monocytes using granulocyte macrophage colony-stimulating factor and IL-13, and matured for 6 hours with Klebsiella-derived cell wall fraction and interferon-gamma (IFN-γ). DCs were also loaded with 6 HLA-A*0201 binding peptides derived from carcinoembryonic antigen (CEA), MAGE, and HER2/neu, as well as keyhole limpet hemocyanin protein and pan-DR epitope peptide. Four planned doses of 35×10 cells were administered intradermally every 3 weeks. Immune response was assessed by IFN-γ enzyme-linked immunosorbent spot (ELISPOT). Matured DC possessed an activated phenotype and could prime T cells in vitro. In the trial, 21 HLA-A2+ patients were apheresed, 13 were treated with the vaccine, and 11 patients were evaluable. No significant treatment-related toxicity was reported. T-cell responses to a CEA-derived peptide were detected by ELISPOT in 3 patients. T cells induced to CEA possessed high avidity T-cell receptors. ELISPOT after in vitro restimulation detected responses to multiple peptides in 2 patients. All patients showed progressive disease. This pilot study in advanced CRC patients demonstrates DC-generated granulocyte macrophage colony-stimulating factor and IL-13 matured with Klebsiella-derived cell wall fraction and IFN-γ can induce immune responses to multiple tumor-associated antigens in patients with advanced CRC.

KW - Carcinoembryonic antigen

KW - Colorectal cancer

KW - Dendritic cell

UR - http://www.scopus.com/inward/record.url?scp=34748832351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748832351&partnerID=8YFLogxK

U2 - 10.1097/CJI.0b013e318133451c

DO - 10.1097/CJI.0b013e318133451c

M3 - Article

C2 - 17893568

AN - SCOPUS:34748832351

VL - 30

SP - 762

EP - 772

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 7

ER -